| Indicators | Browse All

Eikon Therapeutics, Inc. (EIKN)

Healthcare | Biotechnology | Millbrae, United States | NasdaqGS
10.98 USD -0.54 (-4.688%) ⇩ (Aug. 28, 2026, 4 p.m. EDT)
After hours: 10.98

Short-term:★★⯪☆☆Long-term:★★⯪☆☆Dividends:☆☆☆☆☆
Hot Take | Aug. 22, 2026, 6:01 a.m. EDT

The immediate outlook is neutral due to conflicting signals: while the stock recently rallied off its lows, the statistical forecast model offers no directional edge with low confidence, suggesting the recent move may be noise rather than a trend. Fundamentally, the company faces significant headwinds with negative earnings, negative operating cash flow, and a forward P/E that indicates no near-term profitability. The balance sheet shows a healthy liquidity cushion with a current ratio near 10x, which prevents an immediate distress scenario, but the lack of revenue growth and persistent losses make a 'buy' thesis difficult to construct without a specific catalyst. On the long-term horizon, the absence of any multi-year price history prevents an assessment of structural trends, leaving the investment case reliant entirely on future clinical developments and management execution rather than proven business quality. Consequently, there is no compelling reason to overweight the position for either short-term traders or long-term holders at these levels.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.079542
AutoETS0.081115
AutoARIMA0.081115
AutoTheta0.128220

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 35%
H-stat 0.28
Ljung-Box p 0.000
Jarque-Bera p 0.027
Excess Kurtosis 0.18
Attribute Value
Sector Healthcare
Debt to Equity Ratio 54.066
Market Cap 594,732,032
Forward P/E -1.73
Website https://eikontx.com

Info Dump

Attribute Value
52 Week Change -0.268
Address1 230 Harriet Tubman Way
All Time High 17.4
All Time Low 7.9
Ask 11.09
Ask Size 1
Average Analyst Rating 2.0 - Buy
Average Daily Volume10 Day 545,290
Average Daily Volume3 Month 403,326
Average Volume 403,326
Average Volume10Days 545,290
Bid 8.2
Bid Size 2
Book Value 8.615
City Millbrae
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 10.98
Current Ratio 9.892
Custom Price Alert Confidence HIGH
Date Short Interest 1,786,665,600
Day High 11.44
Day Low 10.9
Debt To Equity 54.066
Display Name Eikon Therapeutics
Earnings Timestamp 1,786,651,200
Earnings Timestamp End 1,794,513,600
Earnings Timestamp Start 1,794,513,600
Ebitda -317,228,992
Ebitda Margins 0.0
Enterprise To Ebitda -0.995
Enterprise Value 315,773,024
Eps Current Year -6.41162
Eps Forward -6.33429
Eps Trailing Twelve Months -5.65
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 10.4894
Fifty Day Average Change 0.49059963
Fifty Day Average Change Percent 0.04677099
Fifty Two Week Change Percent -26.800001
Fifty Two Week High 17.4
Fifty Two Week High Change -6.42
Fifty Two Week High Change Percent -0.36896554
Fifty Two Week Low 7.9
Fifty Two Week Low Change 3.0799994
Fifty Two Week Low Change Percent 0.38987336
Fifty Two Week Range 7.9 - 17.4
Financial Currency USD
First Trade Date Milliseconds 1,770,301,800,000
Float Shares 29,869,847
Forward Eps -6.33429
Forward P E -1.7334223
Full Exchange Name NasdaqGS
Full Time Employees 384
Fullday Change -0.540001
Fullday Change Percent -4.68751
Fullday Price 10.98
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.17377001
Held Percent Institutions 0.69184
Implied Shares Outstanding 54,165,030
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,026-02-05
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.
Long Name Eikon Therapeutics, Inc.
Market us_market
Market Cap 594,732,032
Market State CLOSED
Max Age 86,400
Message Board Id finmb_638227772
Most Recent Quarter 1,782,777,600
Net Income To Common -322,160,992
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 623,439,495
Number Of Analyst Opinions 5
Open 11.41
Operating Cashflow -256,018,000
Operating Margins 0.0
Payout Ratio 0.0
Phone 341 777 0566
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 10.98
Post Market Time 1,787,959,806
Previous Close 11.52
Price Eps Current Year -1.7125156
Price Hint 2
Price To Book 1.2745211
Profit Margins 0.0
Quick Ratio 9.606
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key buy
Recommendation Mean 2.0
Region US
Regular Market Change -0.540001
Regular Market Change Percent -4.68751
Regular Market Day High 11.44
Regular Market Day Low 10.9
Regular Market Day Range 10.9 - 11.44
Regular Market Open 11.41
Regular Market Previous Close 11.52
Regular Market Price 10.98
Regular Market Time 1,787,947,201
Regular Market Volume 239,636
Sand P52 Week Change 0.20204377
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 54,165,030
Shares Percent Shares Out 0.077199996
Shares Short 4,179,636
Shares Short Previous Month Date 1,784,073,600
Shares Short Prior Month 4,627,639
Short Name Eikon Therapeutics, Inc.
Short Percent Of Float 0.1025
Short Ratio 12.79
Source Interval 15
State CA
Symbol EIKN
Target High Price 32.0
Target Low Price 4.0
Target Mean Price 24.6
Target Median Price 29.0
Total Cash 531,177,984
Total Cash Per Share 9.807
Total Debt 252,219,008
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -5.65
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 11.1267605
Two Hundred Day Average Change -0.14676094
Two Hundred Day Average Change Percent -0.013189907
Type Disp Equity
Volume 239,636
Website https://eikontx.com
Zip 94,030